{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '6. A recent microarray genomics study, using orbital fat samples from TED patients,', 'showed that active disease has a marked dysregulation of genes in the IGF/IGF-1R', 'signaling pathway [Ezra et al, 2011].', '7. Experiments with human orbital fibroblasts and thyrocytes suggest that IGF-1R is', 'physically associated with TSHR. Moreover, inhibiting IGF-1R with an antagonist', 'antibody also has the effect of reducing signaling through TSHR [Tsui et al, 2008].', 'Remarkably, this work suggests that the 2 major autoantigens implicated in TED are', 'physically and functionally coupled.', '7.1.3 Teprotumumab', 'Teprotumumab (HZN-001) is a fully human immunoglobulin G1 (IgG1) mAb directed against', 'human IGF-1R. The IGF-1R is a tyrosine kinase cell surface receptor that shares ~50% overall', 'homology with the insulin receptor [Ullrich et al, 1986]. Teprotumumab binds with high affinity', 'and selectivity to the extracellular domain of IGF-1R and prevents its activation by the', 'endogenous ligands, IGF-1 and IGF-2. Teprotumumab has no partial agonist activity at IGF-1R,', 'as assessed by activation of the canonical signaling pathway (phosphoinositide 3 kinase/Akt),', 'and has no affinity for the insulin receptor. In addition, teprotumumab causes direct inactivation', 'of IGF-1R through antibody-induced cellular internalization and degradation. Binding of', 'teprotumumab has been shown to inhibit canonical signal transduction and cellular proliferation', 'and survival functions mediated by IGF-1R in cancer cells. Teprotumumab does not induce', 'antibody-dependent cellular cytotoxicity.', 'Teprotumumab was originally developed by F. Hoffman-La Roche, Ltd., for the treatment of', 'subjects with advanced solid tumors, including sarcoma. In vitro and in vivo studies suggest that', 'IGFs play important roles in the development and progression of cancer. Details of the', 'development of the compound (previously identified as RO4858696 or R1507) in the oncology', \"indication are provided in the Horizon Investigator's Brochure (IB) [Investigator's Brochure,\", '2017]. Roche is no longer pursuing development of teprotumumab in oncology indications.', 'Development was terminated due to inadequate efficacy in cancer indications, not to any', 'observed side effects or safety issues.', 'River Vision Development Corporation licensed teprotumumab for development in the orphan', 'indication of TED. Horizon Pharma acquired River Vision Development Corporation in May of', '2017 and will continue the development of teprotumumab for TED.', '7.1.3.1 Physiochemical Properties', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 54 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '7.1.3.2 Safety Pharmacology', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 55 of 118']\n\n###\n\n", "completion": "END"}